+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying FMC-376 alone and combined with pembrolizumab in adults with advanced solid tumors that have the KRAS G12C mutation. This clinical trial includes three parts Phase 1A Dose Escalation, Phase 1B Dose Expansion, and Phase 2 Cohort Expansion. It aims to evaluate multiple dose levels and assess safety, pharmacokinetics, and clinical activity in participants with these tumors. Participants will receive FMC-376 orally daily in 21-day cycles, either as monotherapy or combined with pembrolizumab. The study progresses sequentially through dose escalation, dose expansion, and cohort expansion stages to find appropriate dosing and evaluate effects. Those receiving combination therapy must meet additional criteria related to immune health. Throughout the trial, participants will be closely monitored for dose limiting toxicities, adverse events, and overall response over approximately 24 months. Researchers will assess drug levels in blood, response duration, disease control, progression-free and overall survival. The study ensures safety and compliance by evaluating participants health status and organ function regularly.

Age: 18Years +All GendersPhase 1Phase 2
26 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are evaluating how well a lower dose of radiotherapy after chemotherapy works to treat children and young adults with central nervous system CNS germinomas. This Phase II study focuses on using carboplatin and etoposide chemotherapy followed by reduced radiation doses to see if this approach can effectively control the disease while potentially reducing long-term side effects. The study also investigates neuroendocrine function and cognitive processing speed as important outcomes. Participants receive up to four cycles of chemotherapy with carboplatin given intravenously on day 1 and etoposide given intravenously on days 1 through 3 every 21 days. After chemotherapy, patients are assigned to different treatment groups based on their response and tumor characteristics. Radiation therapy options include 3-dimensional conformal radiation, intensity-modulated radiation, or proton therapy with varying doses depending on the specific group. Some patients may undergo second-look surgery to assess tumor response. Blood, cerebrospinal fluid, and tissue samples may be collected throughout the study for further research. During the study, participants undergo regular magnetic resonance imaging MRI scans and may have lumbar punctures for cerebrospinal fluid collection during screening and follow-up. They are monitored for event-free survival, overall survival, tumor response, neuroendocrine function, and cognitive processing speed over several years. Follow-up visits occur every 3 months for the first year, then every 4 months for two years, followed by annual visits for up to 10 years after treatment. This allows researchers to assess long-term effects and outcomes.

Age: 3Years - 29YearsAll GendersPhase 2
115 locations
L

Actively Recruiting

This research aims to evaluate the long-term effect of sepiapterin on preserving brain function in children with Phenylketonuria PKU when treatment begins in early childhood. The study includes children up to 9 years old and focuses on neurocognitive outcomes over several years. The trial has two parts Part 1 is an open-label test to see how participants respond to sepiapterin, and Part 2 is an open-label treatment period. Participants will take age- and weight-adjusted doses of sepiapterin powder orally once daily for up to 6 years. The powder will be mixed with water or apple juice before administration. During the study, children will be regularly assessed with intelligence tests such as the Wechsler Preschool and Primary Scale of Intelligence and the Wechsler Intelligence Scale for Children. Quality of life and blood phenylalanine levels will also be monitored. The researchers will track changes from baseline over 2 to 6 years to evaluate treatment effects. Safety and adherence will be overseen throughout the duration until the study concludes in 2031.

Age: 0 - 9YearsAll GendersPhase 3
14 locations
E

Actively Recruiting

Researchers are conducting an 18-month Phase 3 clinical trial to study the safety and efficacy of oral nizubaglustat AZ-3102 in children and young people aged 4 years and older with late-infantile and juvenile forms of Niemann-Pick Type C NPC disease. This randomized, double-blind, placebo-controlled study aims to compare the effects of nizubaglustat against placebo on ataxic symptoms and other disease manifestations in this rare neurological condition. Participants will receive once-daily oral dispersible tablets of either nizubaglustat or a matching placebo over 18 months. The study examines the drugs pharmacokinetics and pharmacodynamics, along with its safety and tolerability. The trial is conducted at multiple centers and includes a parallel study design where participants are randomly assigned to one of the two groups. Throughout the study, participants will undergo regular assessments including the Scale for the Assessment and Rating of Ataxia SARA, Vineland Adaptive Behavior Scale, Penetration-Aspiration Scale, and several other evaluations at baseline and at months 6, 12, and 18. Researchers will also monitor seizure frequency and drug plasma levels, as well as record any adverse effects. The primary outcomes focus on changes in ataxia scores over the 18-month period to evaluate the treatments impact.

Age: 4Years +All GendersPhase 3
34 locations
P

Actively Recruiting

Researchers are studying the safety and effects of oral nizubaglustat AZ-3102 in children aged 4 years and older with late-infantile or juvenile forms of Niemann-Pick type C disease, GM1 gangliosidosis, or GM2 gangliosidosis. This Phase 3 study is double-blinded, randomized, placebo-controlled, and conducted at multiple centers. It uses a Master Protocol Research Program with different subprotocols for each disease type to evaluate treatment outcomes. Participants are randomly assigned in a 21 ratio to receive either oral nizubaglustat or a matching placebo. The study lasts 18 months and includes separate subprotocols for Niemann-Pick type C disease and for GM1 or GM2 gangliosidosis. Each subprotocol may have additional eligibility criteria and specific safety and efficacy assessments. During the study, participants undergo evaluations defined in their disease-specific subprotocols. Researchers monitor safety and efficacy throughout the 18-month period, tracking the number of participants assigned to each subprotocol. The study aims to gather detailed information on the treatments impact over this timeframe, with continuous monitoring to assess participant health and responses.

Age: 4Years +All GendersPhase 3
39 locations
E

Actively Recruiting

This research aims to study children and adolescents aged 2 to 17 years who have fibrosing interstitial lung disease ILD. The trial evaluates how the drug nerandomilast is tolerated, processed by the body, and whether it helps young patients with ILD. Nerandomilast has been approved in some countries for adults with a similar lung condition called idiopathic pulmonary fibrosis. The study is designed to better understand the effects and safety of nerandomilast in this younger population. Participants aged 6 to 17 years are randomly assigned to one of two groups for the first part of the study one group receives nerandomilast, and the other receives a placebo that looks like the medicine but contains no active drug. They take tablets twice daily for 6 months. After this, all participants in this age group receive nerandomilast for at least 2 years in the second part of the study. Younger participants aged 2 to 5 years start nerandomilast treatment immediately and take the tablets twice daily for at least two and a half years. Over the course of the study, which lasts between two and a half to five years depending on when participants join, individuals may have about 18 to 30 visits to the study site. During these visits, doctors collect blood samples to monitor health and how the body handles the medicine. Lung function, growth, and quality of life are also regularly assessed. For participants aged 6 to 17 years, results from the nerandomilast group are compared to those receiving placebo to evaluate treatment effects.

Age: 2Years - 17YearsAll GendersPhase 3
47 locations
S

Actively Recruiting

Healthy Volunteer

Fetal growth restriction FGR affects many pregnancies and is linked to serious risks including stillbirth, preterm birth, and long-term developmental challenges such as cerebral palsy. This trial evaluates whether giving pregnant women melatonin can protect the fetal brain and improve neurodevelopmental outcomes in babies affected by early-onset severe FGR. The study is a triple-blind, randomized, placebo-controlled trial aiming to address the lack of treatments to enhance fetal wellbeing before birth. Participants will receive either melatonin tablets 10 mg three times daily for a total of 30 mg per day or matching placebo tablets three times a day. The trial includes pregnancies diagnosed with severe FGR between 23 and 31 weeks gestation. Treatment continues until birth. The study is conducted across multiple centers, with participant groups randomized based on gestational age to allow sub-analysis of early and late onset FGR. Participants will be monitored throughout pregnancy with assessments of fetal growth and placental blood flow. After birth, childrens neurodevelopment will be evaluated at 2 years of age using the Bayley-IV Cognitive scale. Researchers will also track side effects, maternal organ function, and fetal wellbeing until birth. The total participation duration varies depending on gestational age at enrollment and follow-up visits extend to 2-3 years of the childs life for outcome measurement.

Age: 18Years +FEMALEPhase 3
12 locations
F

Actively Recruiting

This research aims to evaluate the feasibility and safety of the new Axonics External Trial System ETS-02 in patients with overactive bladder OAB andor fecal incontinence FI. It focuses on determining if patients respond to sacral neuromodulation SNM before receiving the Axonics implantable neurostimulator INS, which is approved for treating OAB and FI. Participants will use the Axonics External Trial System, which involves placing a temporary electrode wire through the S3 foramen, sometimes with imaging guidance. This wire connects to an external pulse generator worn for a trial period of 3 to 7 days to assess responsiveness to SNM. During the study, participants will be monitored for overall feasibility between days 5 and 7 and for any adverse events from the start through day 7. Assessments include bladder or bowel diaries, safety monitoring, and compliance with study visits. The total participation period covers the trial duration and follow-up for safety outcomes.

Age: 18Years +All GendersPhase Not Applicable
5 locations

1-10 of 22

1